1. Home
  2. PLBL vs ADPT Comparison

PLBL vs ADPT Comparison

Compare PLBL & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBL

Polibeli Group Ltd Class A Ordinary Shares

N/A

Current Price

$8.65

Market Cap

3.0B

Sector

N/A

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.06

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBL
ADPT
Founded
2021
2009
Country
Indonesia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PLBL
ADPT
Price
$8.65
$13.06
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$17.78
AVG Volume (30 Days)
2.8K
1.7M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
N/A
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$5.60
$6.68
52 Week High
$13.48
$20.76

Technical Indicators

Market Signals
Indicator
PLBL
ADPT
Relative Strength Index (RSI) 51.85 30.42
Support Level $7.36 $12.32
Resistance Level $9.50 $13.45
Average True Range (ATR) 0.60 0.82
MACD 0.17 -0.29
Stochastic Oscillator 69.45 20.71

Price Performance

Historical Comparison
PLBL
ADPT

About PLBL Polibeli Group Ltd Class A Ordinary Shares

Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: